



MEDICAL SURGICAL VISION CLINICAL PROTOCOL & GUIDELINE

POLICY TITLE	Intravitreal anti-VEGF/Biologic Injections		
CATEGORY	Medical Surgical	POLICY ID NUMBER	300_v2_NY_HF
ORIGINAL EFFECTIVE DATE	01/01/2025	LAST REVIEW DATE	09/05/2024
LAST APPROVAL DATE	11/2024	LAST REVISION DATE	09/05/2024
EXCLUSIONS	Applicable to HealthFirst NY only		
DISCLAIMER	CPT® Codes, Descriptors, and other data are copyright 2024 American Medical Association (or such other date of publication of CPT®). All Rights Reserved to AMA. Additional resources include CMS Medicare Provider Guidelines @ CMS.gov. This information may not be sold, licensed, or unlawfully used and is intellectual property of EyeMed and the aforementioned entities.		

Applicable Codes:

J0177 EYLEA HD (Aflibercept HD) injection – intravitreal injection

Aflibercept HD is a vascular endothelial growth factor (VEGF) inhibitor used for intravitreal injection

J0178 EYLEA (aflibercept) injection- intravitreal injection

Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for intravitreal administration.

J0179 BEOVU (brolucizumab-dbl) injection-intravitreal injection

Brolucizumab-dbl is a human vascular endothelial growth factor (VEGF) inhibitor used as an intravitreal injection.

J2777 VABYSMO (faricimab-svoa) injection-intravitreal injection

Faricimab-SVOA is a vascular endothelial growth factor (VEGF) inhibitor and angiopoietin-2 (Ang-2) inhibitor.

J2778 LUCENTIS (ranibizumab) injection-intravitreal injection

Ranibizumab, a recombinant humanized immunoglobulin G, kappa monoclonal antibody fragment, is a vascular endothelial growth factor A (VEGF-A) antagonist used as an intravitreal injection

1 Indication and Limitations¹

1.1 Medical Necessity

- 1.1.1 Ocular Coherence Tomography (OCT) and/or fluorescein angiography (FA) test results must be interpreted and firmly establish/support diagnosis
- 1.1.2 Appropriate diagnosis and clinical findings must be well-documented
 - 1.1.2.1 Secondary CNV or unlisted diagnosis may be submitted for prior authorization after Avastin trial failure, and all necessary criteria are satisfied.
 - 1.1.2.1.1 Claims will be reviewed on a case-by-case basis.
- 1.1.3 A current and relevant clinical evaluation within the past 6 months is required

1.2 Additional Requirements (applicable for all codes)

- 1.2.1 Procedure note must include:
 - 1.2.1.1 Actual administered drug, dosage, injection site, & route of administration
 - 1.2.1.2 Injection lot # & expiration date
 - 1.2.1.3 Post-injection vision check \geq CF
 - 1.2.1.4 Specific notation patient has been queried/screened for contraindicating/ co-morbidities.
- 1.2.2 Avastin trial failure must clearly be indicated in chart
 - 1.2.2.1 Does not apply to Susvimo
 - 1.2.2.2 Does not apply to new members who are currently on successful intravitreal injection treatment
 - 1.2.2.3 Minimum treatment trial consisting of 3 Avastin (bevacizumab) injections
 - 1.2.2.4 Inadequate clinical response
 - 1.2.2.4.1 Fewer than 3 lines of improvement on visual acuity testing
 - 1.2.2.5 Medical necessity reason for changing therapy from Avastin to one of the above-listed drugs.
- 1.2.3 Pt must have a positive response to treatment of at least two prior injections of ranibizumab to qualify for Susvimo.
- 1.2.4 Informed consent stating all pertinent risks must include:
 - 1.2.4.1 Date, consent to perform/waive, patient or representative signature, surgeon/physician signature, and witness signature
- 1.2.5 Authorization Time frame
 - 1.2.5.1 will be given for the time period of 12 months
 - 1.2.5.2 will cover up to the listed maximum of injections during the time period.
 - 1.2.5.3 Additional requested injections will be subject to review
 - 1.2.5.3.1 determinations will be made on a case-by-case basis and subject to medical necessity.
- 1.2.6 Services should be performed as indicated by current medical literature and/ or standards of practice.

- 1.2.7** When services are performed in excess of established parameters, they may be subject to review for medical necessity.

2 Eylea HD

2.1 Treatment indications with approved dosage schedule

2.1.1 Neovascular (Wet) age-related macular degeneration (AMD)

2.1.1.1 Recommended dose

2.1.1.1.1 8 mg (0.07 mL of 114.3 mg/mL solution)

2.1.1.1.2 administered by intravitreal injection every 4 weeks (approximately every 28 days +/- 7 days) for the first three doses,

2.1.1.1.3 followed by 8 mg (0.07 mL of 114.3 mg/mL solution) via intravitreal injection once every 8 to 16 weeks, +/- 1 week.

2.1.2 Diabetic macular edema (DME)

2.1.2.1 Recommended dose

2.1.2.1.1 8 mg (0.07 mL of 114.3 mg/mL solution)

2.1.2.1.2 administered by intravitreal injection every 4 weeks (approximately every 28 days +/- 7 days) for the first three doses,

2.1.2.1.3 followed by 8 mg (0.07 mL of 114.3 mg/mL solution) via intravitreal injection once every 8 to 16 weeks, +/- 1 week

2.1.3 Diabetic retinopathy (DR)

2.1.3.1 Recommended dose

2.1.3.1.1 8 mg (0.07 mL of 114.3 mg/mL solution)

2.1.3.1.2 administered by intravitreal injection every 4 weeks (approximately every 28 days +/- 7 days) for the first three doses

2.1.3.1.3 followed by 8 mg (0.07 mL of 114.3 mg/mL solution) via intravitreal injection once every 8 to 12 weeks, +/- 1 week.

3 Eylea

3.1 Treatment indications with approved dosage schedule

3.1.1 Neovascular (Wet) age-related macular degeneration (AMD)

3.1.1.1 Recommended dose

3.1.1.1.1 2 milligrams

3.1.1.1.2 administered by intravitreal injection once every 4 weeks (monthly) for the first 12 weeks (3 months),

¹ Physician attests at time of request submission that physician signed documentation across the full timeframe of treatment rendered (chart, procedures, order, testing interpretation) supports all indications and limitations for service based on this policy and industry billing guidance.

- 3.1.1.1.3 THEN 2 milligrams administered by intravitreal injection once every 8 weeks [2 months]
- 3.1.1.1.4 Although EYLEA (aflibercept) may be dosed as frequently as 2 milligrams every 4 weeks (monthly), additional efficacy was not demonstrated when EYLEA (aflibercept) was dosed every 4 weeks as compared to every 8 weeks.
- 3.1.1.1.5 Some patients may require monthly injections after the initial 3-month period
- 3.1.1.2 Utilization Guidelines (as determined by health plan)
 - 3.1.1.2.1 Max injections per calendar year = 16
- 3.1.2 Diabetic macular edema (DME) & Diabetic retinopathy
 - 3.1.2.1 Recommended dose
 - 3.1.2.1.1 2 milligrams
 - 3.1.2.1.2 administered by intravitreal injection once every 4 weeks (monthly) for the first 20 weeks (5 months)
 - 3.1.2.1.3 THEN 2 milligrams administered by intravitreal injection once every 8 weeks (2 months)
 - 3.1.2.1.4 Some patients may require monthly injections after the initial 5-month period
- 3.1.3 Macular edema associated with retinal vein occlusion.
 - 3.1.3.1 Recommended dose
 - 3.1.3.1.1 2 milligrams
 - 3.1.3.1.2 administered by intravitreal injection once every 4 weeks (monthly)
- 3.1.4 Retinopathy of Prematurity (ROP)
 - 3.1.4.1 Recommended dose
 - 3.1.4.1.1 0.4 mg (0.01 mL or 10 microliters of 40 mg/mL solution)
 - 3.1.4.1.2 administered by intravitreal injection.
 - 3.1.4.1.3 Treatment may be given bilaterally on the same day.
 - 3.1.4.1.4 Injections may be repeated in each eye.
 - 3.1.4.1.5 The treatment interval between doses injected into the same eye should be at least 10 days.

4 Beovu

4.1 Treatment indications with approved dosage schedule

- 4.1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD)
 - 4.1.1.1 Recommended dose
 - 4.1.1.1.1 6 milligrams (0.05 mL of 120 mg/mL solution)
 - 4.1.1.1.2 Administered by intravitreal injection monthly (approximately every 25-31 days) for the first three doses,
 - 4.1.1.1.3 followed by one dose of 6 milligrams (0.05 mL) every 8-12 weeks
 - 4.1.1.2 Utilization Guidelines

4.1.1.2.1 Max injections per calendar year = 16

4.1.2 Diabetic Macular Edema (DME)

4.1.2.1 Recommended dose

4.1.2.1.1 6 milligrams (0.05 mL of 120 mg/mL solution)

4.1.2.1.2 every six weeks (approximately every 39-45 days) for the first five doses

4.1.2.1.3 followed by one dose of 6 milligrams (0.05 mL of 120 mg/mL solution) every 8-12 weeks

4.1.2.2 Utilization Guidelines

4.1.2.2.1 Max injections per calendar year = 16

5 Vabysmo

5.1 Treatment indications with approved dosage schedule

5.1.1 Neovascular (Wet) Age-Related Macular Degeneration (nAMD)

5.1.1.1 Recommended dose

5.1.1.1.1 6 mg (0.05 mL of 120 mg/mL solution)

5.1.1.1.2 administered by intravitreal injection every 4 weeks (approximately every 28 ± 7 days, monthly) for the first 4 doses

5.1.1.1.3 followed by optical coherence tomography and visual acuity evaluations 8 and 12 weeks later to inform whether to give a 6 mg dose via intravitreal injection on one of the following three regimens: 1) Weeks 28 and 44; 2) Weeks 24, 36 and 48; or 3) Weeks 20, 28, 36 and 44.

5.1.1.1.4 Although additional efficacy was not demonstrated in most patients when VABYSMO was dosed every 4 weeks compared to every 8 weeks

5.1.1.1.5 some patients may need every 4 week (monthly) dosing after the first 4 doses. Patients should be assessed regularly. (2.2)

5.1.2 Diabetic Macular Edema (DME)

5.1.2.1 Recommended dosage

5.1.2.1.1 6 mg (0.05 mL of 120 mg/mL solution)

5.1.2.1.2 administered by intravitreal injection every 4 weeks (approximately every 28 days ± 7 days, monthly) for at least 4 doses.

5.1.2.1.3 If after at least 4 doses, resolution of edema based on the central subfield thickness (CST) of the macula as measured by optical coherence tomography is achieved, then the interval of dosing may be modified by extensions of up to 4 week interval increments or reductions of up to 8 week interval increments based on CST and visual acuity evaluations; OR

5.1.2.1.4 6 mg dose can every 4 weeks for the first 6 doses, followed by 6 mg dose via intravitreal injection at intervals of every 8 weeks (2 months).

5.1.2.1.5 Although additional efficacy was not demonstrated in most patients when VABYSMO was dosed every 4 weeks compared to every 8 weeks, some patients may need every 4 week (monthly) dosing after the first 4 doses. Patients should be assessed regularly.

5.1.2.2 Utilization Guidelines

5.1.2.2.1 Max injections per calendar year = 16

5.1.2.2.2 more frequent dosing approved at discretion

6 Lucentis

6.1 Treatment indication with approved dosage schedule

6.1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD)

6.1.1.1 Recommended dosage

6.1.1.1.1 0.5 milligrams (0.05 mL)

6.1.1.1.2 administered by intravitreal injection once a month (approximately 28 days).

6.1.1.1.3 Although not as effective, patients may be treated with 3 monthly doses followed by less frequent dosing with regular assessment.

6.1.1.1.4 Although not as effective, patients may also be treated with one dose every 3 months after 4 monthly doses.

6.1.1.1.5 Patients should be assessed regularly.

6.1.1.2 Utilization Guidelines

6.1.1.2.1 Max injections per calendar year = 26

6.1.2 Macular Edema Following Retinal Vein Occlusion (RVO)

6.1.2.1 Recommended dosage

6.1.2.1.1 0.5 milligrams (0.05 mL)

6.1.2.1.2 administered by intravitreal injection once a month (approximately 28 days).

6.1.2.2 Utilization Guidelines

6.1.2.2.1 Max injections per calendar year = 26

6.1.3 Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)

6.1.3.1 Recommended dosage

6.1.3.1.1 0.3 milligrams (0.05 mL)

6.1.3.1.2 administered by intravitreal injection once a month (approximately 28 days)

6.1.3.2 Utilization Guidelines

6.1.3.2.1 Max injections per calendar year = 26

6.1.4 Myopic Choroidal Neovascularization (mCNV)

6.1.4.1 Recommended dosage

6.1.4.1.1 0.5 mg (0.05 mL)

6.1.4.1.2 administered by intravitreal injection once a month (approximately 28 days) for up to three months.

- 6.1.4.1.3** Patients may be retreated if needed
- 6.1.4.2** Utilization Guidelines
 - 6.1.4.2.1** Max injections per calendar year = 8

7 Supporting Diagnoses

7.1 EYLEA HD (Aflibercept HD) injection-intravitreal injection *listed as Group 5 on LCD article*

E08.311	Diabetes Mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema
E08.319	Diabetes Mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema
E08.3211-E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)
E08.3291- E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E08.3311- E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)
E08.3391- E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E08.3411- E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)
E08.3491- E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E08.3511- E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)
E08.3521- E08.3523	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, (right eye, left eye, bilateral)
E08.3531- E08.3533	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, (right eye, left eye, bilateral)
E08.3541- E08.3543	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, (right eye, left eye, bilateral)
E08.3551- E08.3553	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, (right eye, left eye, bilateral)
E08.3591- E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E09.311	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema
E09.319	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema
E09.3211-E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)

7.1 EYLEA HD (Aflibercept HD) injection-intravitreal injection listed as Group 5 on LCD article

E09.3291-E09.3293	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E09.3311-E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)
E09.3391-E09.3393	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E09.3411-E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)
E09.3491-E09.3493	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E09.3511-E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)
E09.3521-E09.3523	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, (right eye, left eye, bilateral)
E09.3531-E09.3533	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, (right eye, left eye, bilateral)
E09.3541-E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, (right eye, left eye, bilateral)
E09.3551-E09.3553	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, (right eye, left eye, bilateral)
E09.3591-E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema
E10.3211-E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)
E10.3291-E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E10.3311-E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)
E10.3391-E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E10.3411-E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)

7.1 EYLEA HD (Aflibercept HD) injection-intravitreal injection listed as Group 5 on LCD article

E10.3491-E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E10.35.11-E10.35.13	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)
E10.35.21-E10.35.23	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, (right eye, left eye, bilateral)
E10.35.31-E10.35.33	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, (right eye, left eye, bilateral)
E10.35.41-E10.35.43	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, (right eye, left eye, bilateral)
E10.35.51-E10.35.53	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, (right eye, left eye, bilateral)
E10.35.91-E10.35.93	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema
E11.3211-E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)
E11.3291-E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E11.3311-E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)
E11.3391-E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E11.3411-E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)
E11.3491-E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E11.3511-E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)
E11.3521-E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, (right eye, left eye, bilateral)
E11.3531-E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, (right eye, left eye, bilateral)

7.1 EYLEA HD (Aflibercept HD) injection-intravitreal injection listed as Group 5 on LCD article

E11.3541-E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, (right eye, left eye, bilateral)
E11.3551-E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, (right eye, left eye, bilateral)
E11.3591-E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema
E13.3211- E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)
E13.3291- E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E13.3311- E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)
E13.3391- E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E13.3411- E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)
E13.3491- E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E13.3511- E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)
E13.3521- E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, (right eye, left eye, bilateral)
E13.3531- E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, (right eye, left eye, bilateral)
E13.3541- E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, (right eye, left eye, bilateral)
E13.3551- E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, (right eye, left eye, bilateral)
E13.3591- E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
H35.3210	Exudative age-related macular degeneration, right eye, stage unspecified
H35.3211	Exudative age-related macular degeneration, right eye, with active choroidal neovascularization
H35.3212	Exudative age-related macular degeneration, right eye, with inactive choroidal neovascularization

7.1 EYLEA HD (Aflibercept HD) injection-intravitreal injection listed as Group 5 on LCD article

H35.3213	Exudative age-related macular degeneration, right eye, with inactive scar
H35.3220	Exudative age-related macular degeneration, left eye, stage unspecified
H35.3221	Exudative age-related macular degeneration, left eye, with active choroidal neovascularization
H35.3222	Exudative age-related macular degeneration, left eye, with inactive choroidal neovascularization
H35.3223	Exudative age-related macular degeneration, left eye, with inactive scar
H35.3230	Exudative age-related macular degeneration, bilateral, stage unspecified
H35.3231	Exudative age-related macular degeneration, bilateral, with active choroidal neovascularization
H35.3232	Exudative age-related macular degeneration, bilateral, with inactive choroidal neovascularization
H35.3233	Exudative age-related macular degeneration, bilateral, with inactive scar
H35.351-H35.353	Cystoid macular degeneration, (right eye, left eye, bilateral)
H35.81	Retinal edema

7.2 EYLEA (aflibercept) injection- intravitreal injection listed as Group 2 on LCD article

E08.311	Diabetes Mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema
E08.319	Diabetes Mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema
E08.3211-E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema,
E08.3291- E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema,
E08.3311- E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema,
E08.3391- E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema,
E08.3411- E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema,
E08.3491- E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema,
E08.3591- E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema,
E09.311	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema
E09.319	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema
E09.3211-E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema

7.2 EYLEA (aflibercept) injection- intravitreal injection listed as Group 2 on LCD article

E09.3291-E09.3293	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral
E09.3311-E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema
E09.3391-E09.3393	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema,
E09.3411-E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema,
E09.3491-E09.3493	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema
E09.3511-E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema
E09.3521-E09.3523	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula
E09.3531-E09.3533	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula
E09.3541-E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment
E09.3551-E09.3553	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy
E09.3591-E09.3593	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema
E10.3211-E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema
E10.3291-E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema
E10.3311-E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema
E10.3391-E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema
E10.3411-E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema
E10.3491-E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema
E10.35.11-E10.35.13	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema
E10.35.21-E10.35.23	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula
E10.35.31-E10.35.33	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula

7.2 EYLEA (aflibercept) injection- intravitreal injection listed as Group 2 on LCD article

E10.35.41-E10.35.43	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment
E10.35.51-E10.35.53	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy
E10.35.91-E10.35.93	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy without macular edema
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema
E11.3211-E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema
E11.3291-E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema
E11.3311-E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema
E11.3391-E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema
E11.3411-E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema
E11.3491-E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema
E11.3511-E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema
E11.3521-E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula
E11.3531-E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula,
E11.3541-E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment
E11.3551-E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy
E11.3591-E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema
E13.3211- E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema
E13.3291- E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema
E13.3311- E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema
E13.3391- E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema

7.2 EYLEA (aflibercept) injection- intravitreal injection listed as Group 2 on LCD article

E13.3411- E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema
E13.3491- E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema
E13.3511- E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema
E13.3521- E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula,
E13.3531- E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula
E13.3541- E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment
E13.3551- E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy
E13.3591- E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema
H34.8110	Central retinal vein occlusion, right eye, with macular edema
H34.8111	Central retinal vein occlusion, right eye, with retinal neovascularization
H34.8112	Central retinal vein occlusion, right eye, stable
H34.8120	Central retinal vein occlusion, left eye, with macular edema
H34.8121	Central retinal vein occlusion, left eye, with retinal neovascularization
H34.8122	Central retinal vein occlusion, left eye, stable
H34.8130	Central retinal vein occlusion, bilateral, with macular edema
H34.8131	Central retinal vein occlusion, bilateral, with retinal neovascularization
H34.8132	Central retinal vein occlusion, bilateral, stable
H34.8310	Tributary (branch) retinal vein occlusion, right eye, with macular edema
H34.8311	Tributary (branch) retinal vein occlusion, right eye, with retinal neovascularization
H34.8312	Tributary (branch) retinal vein occlusion, right eye, stable
H34.8320	Tributary (branch) retinal vein occlusion, left eye, with macular edema
H34.8321	Tributary (branch) retinal vein occlusion, left eye, with retinal neovascularization
H34.8322	Tributary (branch) retinal vein occlusion, left eye, stable
H34.8330	Tributary (branch) retinal vein occlusion, bilateral, with macular edema
H34.8331	Tributary (branch) retinal vein occlusion, bilateral, with retinal neovascularization
H34.8332	Tributary (branch) retinal vein occlusion, bilateral, stable
H35.3210	Exudative age-related macular degeneration, right eye, stage unspecified
H35.3211	Exudative age-related macular degeneration, right eye, with active choroidal neovascularization
H35.3212	Exudative age-related macular degeneration, right eye, with inactive choroidal neovascularization
H35.3213	Exudative age-related macular degeneration, right eye, with inactive scar
H35.3220	Exudative age-related macular degeneration, left eye, stage unspecified
H35.3221	Exudative age-related macular degeneration, left eye, with active choroidal neovascularization

7.2 EYLEA (aflibercept) injection- intravitreal injection listed as Group 2 on LCD article

H35.3222	Exudative age-related macular degeneration, left eye, with inactive choroidal neovascularization
H35.3223	Exudative age-related macular degeneration, left eye, with inactive scar
H35.3230	Exudative age-related macular degeneration, bilateral, stage unspecified
H35.3231	Exudative age-related macular degeneration, bilateral, with active choroidal neovascularization
H35.3232	Exudative age-related macular degeneration, bilateral, with inactive choroidal neovascularization
H35.3233	Exudative age-related macular degeneration, bilateral, with inactive scar
H35.351-H35.353	Cystoid macular degeneration
H35.81	Retinal edema

7.3 BEOVU (brolucizumab-dbl) injection-intravitreal injection listed as Group 3 on LCD article

H35.3210	Exudative age-related macular degeneration, right eye, stage unspecified
H35.3211	Exudative age-related macular degeneration, right eye, with active choroidal neovascularization
H35.3212	Exudative age-related macular degeneration, right eye, with inactive choroidal neovascularization
H35.3213	Exudative age-related macular degeneration, right eye, with inactive scar
H35.3220	Exudative age-related macular degeneration, left eye, stage unspecified
H35.3221	Exudative age-related macular degeneration, left eye, with active choroidal neovascularization
H35.3222	Exudative age-related macular degeneration, left eye, with inactive choroidal neovascularization
H35.3223	Exudative age-related macular degeneration, left eye, with inactive scar
H35.3230	Exudative age-related macular degeneration, bilateral, stage unspecified
H35.3231	Exudative age-related macular degeneration, bilateral, with active choroidal neovascularization
H35.3232	Exudative age-related macular degeneration, bilateral, with inactive choroidal neovascularization
H35.3233	Exudative age-related macular degeneration, bilateral, with inactive scar

7.4 VABYSMO (faricimab-svoa) injection-intravitreal injection listed as Group 4 on LCD article

E08.311	Diabetes Mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema
E08.3211-E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema,
E08.3311- E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema,
E08.3411- E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema,
E08.3511- E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema
E09.311	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema
E09.3211-E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema
E09.3311-E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema
E09.3411-E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema,
E09.3511-E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema
E10.3211-E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema
E10.3311-E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema
E10.3411-E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema
E10.35.11-E10.35.13	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema
E13.3211- E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema
E13.3311- E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema
E13.3411- E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema
E13.3511- E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema
H34.8110-H34.8112	Central retinal vein occlusion, right eye, (with macular edema, with retinal neovascularization, stable)

7.4 VABYSMO (faricimab-svoa) injection-intravitreal injection listed as Group 4 on LCD article

H34.8120-H34.8122	Central retinal vein occlusion, left eye, (with macular edema, with retinal neovascularization, stable)
H34.8130-H34.8132	Central retinal vein occlusion, bilateral, (with macular edema, with retinal neovascularization, stable)
H34.8310-H34.8312	Tributary (branch) retinal vein occlusion, right eye, (with macular edema, with retinal neovascularization, stable)
H34.8320-H34.8322	Tributary (branch) retinal vein occlusion, left eye, (with macular edema, with retinal neovascularization, stable)
H34.8330-H34.8332	Tributary (branch) retinal vein occlusion , bilateral, (with macular edema, with retinal neovascularization, stable)
H35.3210	Exudative age-related macular degeneration, right eye, stage unspecified
H35.3211	Exudative age-related macular degeneration, right eye, with active choroidal neovascularization
H35.3212	Exudative age-related macular degeneration, right eye, with inactive choroidal neovascularization
H35.3213	Exudative age-related macular degeneration, right eye, with inactive scar
H35.3220	Exudative age-related macular degeneration, left eye, stage unspecified
H35.3221	Exudative age-related macular degeneration, left eye, with active choroidal neovascularization
H35.3222	Exudative age-related macular degeneration, left eye, with inactive choroidal neovascularization
H35.3223	Exudative age-related macular degeneration, left eye, with inactive scar
H35.3230	Exudative age-related macular degeneration, bilateral, stage unspecified
H35.3231	Exudative age-related macular degeneration, bilateral, with active choroidal neovascularization
H35.3232	Exudative age-related macular degeneration, bilateral, with inactive choroidal neovascularization
H35.3233	Exudative age-related macular degeneration, bilateral, with inactive scar

7.5 LUCENTIS (ranibizumab) injection-intravitreal injection & Biosimilars listed as Group 1 on LCD Article

E08.311	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema
E08.319	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema
E08.3211- E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema
E08.3291- E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema
E08.3311- E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema

7.5 LUCENTIS (ranibizumab) injection-intravitreal injection & Biosimilars listed as Group 1 on LCD Article

E08.3391- E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral
E08.3411- E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E08.3491- E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema
E08.3511- E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema
E08.3521- E08.3523	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula,
E08.3531- E08.3533	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula
E08.3541- E08.3543	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment,
E08.3551- E08.3553	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy
E08.3591- E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema
E09.311	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema
E09.319	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema
E09.3211-E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E09.3291- E09.3293	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye
E09.3311- E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema
E09.3391- E09.3393	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema
E09.3411- E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema,
E09.3491- E09.3493	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema
E09.3511- E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema
E09.3521- E09.3523	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula
E09.3531- E09.3533	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula
E09.3541- E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment
E09.3551- E09.3553	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy

7.5 LUCENTIS (ranibizumab) injection-intravitreal injection & Biosimilars listed as Group 1 on LCD Article

E09.3591- E09.3593	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema
E10.3211-E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema
E10.3291-E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema
E10.3311-E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema
E10.3391-E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema
E10.3411-E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema
E10.3491-E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema
E10.3511-E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema
E10.3521-E10.3523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula
E10.3531-E10.3533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula,
E10.3541-E10.3543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment
E10.3551-E10.3553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy
E10.3591-E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema
E11.3211- E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with Macular edema
E11.3291- E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema
E11.3311-E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema
E11.3391- E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema
E11.3411- E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema
E11.3491- E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema

7.5 LUCENTIS (ranibizumab) injection-intravitreal injection & Biosimilars listed as Group 1 on LCD Article

E11.3511-E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema
E11.3521- E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula
E11.3531- E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula
E11.3541- E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment
E11.3551- E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy
E11.3591- E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema
E13.3211- E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema
E13.3291- E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema
E13.3311- E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema
E13.3391-E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema
E13.3411- E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema
E13.3491- E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema
E13.3511- E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema
E13.3521- E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula
E13.3531- E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula
E13.3541- E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment
E13.3551- E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy
E13.3591- E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema
H34.8110	Central retinal vein occlusion, right eye, with macular edema
H34.8111	Central retinal vein occlusion, right eye, with retinal neovascularization
H34.8112	Central retinal vein occlusion, right eye, stable
H34.8120	Central retinal vein occlusion, left eye, with macular edema

7.5 LUCENTIS (ranibizumab) injection-intravitreal injection & Biosimilars listed as Group 1 on LCD Article

H34.8121	Central retinal vein occlusion, left eye, with retinal neovascularization
H34.8122	Central retinal vein occlusion, left eye, stable
H34.8130	Central retinal vein occlusion, bilateral, with macular edema
H34.8131	Central retinal vein occlusion, bilateral, with retinal neovascularization
H34.8132	Central retinal vein occlusion, bilateral, stable
H34.8310	Tributary (branch) retinal vein occlusion, right eye, with macular edema
H34.8311	Tributary (branch) retinal vein occlusion, right eye, with retinal neovascularization
H34.8312	Tributary (branch) retinal vein occlusion, right eye, stable
H34.8320	Tributary (branch) retinal vein occlusion, left eye, with macular edema
H34.8321	Tributary (branch) retinal vein occlusion, left eye, with retinal neovascularization
H34.8322	Tributary (branch) retinal vein occlusion, left eye, stable
H34.8330	Tributary (branch) retinal vein occlusion, bilateral, with macular edema
H34.8331	Tributary (branch) retinal vein occlusion, bilateral, with retinal neovascularization
H34.8332	Tributary (branch) retinal vein occlusion, bilateral, stable
H35.051-H35.053	Retinal neovascularization, unspecified
H35.3210-H35.3213	Exudative age-related macular degeneration, right eye, (stage unspecified, with active choroidal neovascularization, with inactive scar)
H35.3220-H35.3223	Exudative age-related macular degeneration, left eye, (stage unspecified, with active choroidal neovascularization, with inactive scar)
H35.3230-H35.3233	Exudative age-related macular degeneration, bilateral, (stage unspecified, with active choroidal neovascularization, with inactive scar)
H35.351-H35.353	Cystoid macular degeneration
H35.81	Retinal edema
H44.2A1-H44.2A3	Degenerative myopia with choroidal neovascularization

References

- Beovu (brolucizumab). [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; December 2022.
- Eylea (aflibercept). [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals Incorporated; February 2023.
- Eylea HD (aflibercept HD). [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals Incorporated; December 2023.
- CGS Administrators, LLC. Local Coverage Article. “(A52451) Billing and Coding: Ranibizumab and biosimilars, Aflibercept, Aflibercept HD, Brolucizumab-dblI and Faricimab-svoa”. Revision date 01/01/2024. Jurisdiction J-06 and J-K.
- CGS Administrators, LLC. Local Coverage Article. “(A53387) Billing and Coding: Aflibercept (Eylea)” Lucentis (ranizumab). [prescribing information]. South San Francisco, CA: Genentech Incorporated; March 2018.
- CGS Administrators, LLC. Local Coverage Determination.”(L33394) Drugs and Biologicals, Coverage of, for label and Off-Label Uses. Jurisdiction J-06 and J-K.
- Vabysmo (faricimab-svoa). [package insert]. South San Francisco, CA: Genentech Incorporated; January 2023.

Review and Approval Change Log

August 2023	Medical Surgical policy drafted for NY
January 2024	Effective for NY prior authorization
September 2024	Clinical edits updated
November 2024	Approved by HealthFirst Medical Team